C21orf58

Across TCGA pan-cancer cohorts, C21orf58 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C21orf58 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher C21orf58 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C21orf58 expression acts as an unfavorable survival marker.

STAD, ESCA, and SARC are the cancer types where C21orf58 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.212	0.686	.008	30	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C21orf58–STAD (OS)

Open the STAD breakdown →